Vasectomy News and Research

RSS

A vasectomy is a surgical procedure that makes a man sterile, or unable to get a woman pregnant. It is generally considered to be at least as effective as female sterilization and is simpler to perform, safer, and less costly. A vasectomy is done by blocking the tube, called the vas deferens, through which sperm normally pass from each testicle on the way to the seminal vesicle, forming semen.

UCLA urologist debunks 5 common myths about vasectomies

Men can be very concerned about what happens during, and after, a vasectomy - specifically how it will affect them personally. Dr. Jesse Mills, a clinical professor of urology and director of The Men's Clinic at UCLA, says the many myths surrounding the procedure can make men rethink what is often a smart choice for them.

20 Jul 2016

Age, race and family history are the biggest risk factors for prostate cancer, new research suggests

New research suggests that age, race and family history are the biggest risk factors for a man to develop prostate cancer, although high blood pressure, high cholesterol, vitamin D deficiency, inflammation of prostate, and vasectomy also add to the risk. In contrast, obesity, alcohol abuse, and smoking show a negative association with the disease.

30 Sep 2015

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

25 Jul 2015

MES announces worldwide release of new automated sperm quality analyzer

Medical Electronic Systems today announced the worldwide release of the SQA-Vision, the company's new automated sperm quality analyzer. The SQA-Vision was developed based on 10 years of market feedback and is positioned to augment the company's line of SQA-V and QwikCheck semen analyzers with a top of the line solution.

17 Jul 2015

Robert B. Kiningham receives Founders' Award at 2015 AMSSM Annual Meeting

Robert B. Kiningham, MD, was awarded the Founders' Award at the 24th American Medical Society for Sports Medicine Annual Meeting in Hollywood, Fla. The award is bestowed when AMSSM leadership determines that a member exemplifies the best that a sports medicine physician can be and do.

16 Apr 2015

Vasectomy associated with small increased risk of prostate cancer

Vasectomy was associated with a small increased risk of prostate cancer, and a stronger risk for advanced or lethal prostate cancer according to a new study from Harvard School of Public Health.

10 Jul 2014

Chesapeake Urology for Kids introduced for pediatric care

Chesapeake Urology Associates, PA, the premier urology practice in Maryland and the Mid-Atlantic region, introduces Chesapeake Urology for Kids, a comprehensive program to treat urologic conditions in children from pre-natal to 18 years of age. This new division is being led by Robert Mevorach, MD, a fellowship trained pediatric urologist. An office exclusively for pediatric patients is now open at 25 Crossroads Drive in Owings Mills, Maryland.

31 Jan 2014

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

Adverse fetal growth, exposure to maternal smoking correlated with lower measures of sperm quality

Studies over the past 20 years have suggested (though not unequivocally confirmed) that semen quality is in decline, reflected most evidently in falling sperm counts and reduced sperm motility.

8 Jul 2013

European Commission amends marketing authorisation for Celgene's REVLIMID

Celgene International Sàrl was today notified that the European Commission has amended the marketing authorisation for REVLIMID. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

17 Jun 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Roundup: Abortion bill heads to Mich. Gov's desk; Calif. health care special session priorities; Nurse practitioner role debated in Minn.

An omnibus abortion bill, approved by the Senate on Wednesday, passed the House early this morning by a 72-35 vote, after a controversial requirement that an aborted fetus be buried, cremated or interred was removed earlier this week. Democrats offered a handful of amendments, some referred to as "what's good for the goose is good for the gander," to require men to undergo physical exams before being prescribed Viagra or to get a vasectomy. But all the amendments were shot down. Gov. Rick Snyder is expected to sign the bill into law.

14 Dec 2012

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene International Sàrl today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA.

11 Dec 2012

AUA introduces new guidelines for treatment of OAB, urodynamics, hematuria and vasectomy

The American Urological Association (AUA) introduces new clinical guidelines for the treatment of Overactive Bladder, Urodynamics, Hematuria, and Vasectomy.

24 Oct 2012

Roughly two in five women in the U.S. do not use any form of birth control: Survey

Roughly two in five women in the United States do not use any form of birth control and many underestimate their risk for pregnancy, according to a recent survey about contraceptive practices in the United States.

13 Sep 2012

WHO commits to fast-track assessment of new and existing quality contraceptives

WHO today committed to fast-track its assessment of new and existing quality contraceptives so more women in low- and middle-income countries can obtain and use a broader range of safe and effective contraceptive products.

12 Jul 2012

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that results from three phase III studies evaluating the use of continuous REVLIMID(lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine.

11 May 2012

UM hosts symposium on next generation characterization tools for therapeutic proteins

In a concerted effort to boost regional collaboration on developing new protein drug and diagnostics, the University of Maryland (UM) School of Pharmacy has hosted the first Interdisciplinary Symposium on Next Generation Characterization Tools for Therapeutic Proteins.

16 Apr 2012